CorMedix Inc. - Common Stock (CRMD)
12.50
-2.46 (-16.44%)
NASDAQ · Last Trade: Jun 28th, 7:18 PM EDT
Via Benzinga · June 27, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · June 27, 2025
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.
Via Stocktwits · June 27, 2025
Via Benzinga · June 26, 2025
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 26, 2025
Via Benzinga · June 24, 2025
DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval.
Via Stocktwits · June 23, 2025
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.
Via Investor's Business Daily · June 23, 2025
CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.
Via Benzinga · June 23, 2025
Via Benzinga · June 23, 2025
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.
Via Stocktwits · May 6, 2025
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.
Via Stocktwits · April 8, 2025
Via Benzinga · April 8, 2025
CRMD earnings call for the period ending December 31, 2024.
Via The Motley Fool · March 25, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · March 25, 2025
Via Benzinga · March 25, 2025
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · March 25, 2025
The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.
Via Stocktwits · March 25, 2025
Via Benzinga · March 25, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · March 25, 2025